Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that has never been approved by any regulator, anywhere, for any use. It binds melanocortin receptors and stimulates melanin production, which is why it became known as a tanning compound. Its human efficacy evidence consists of a single phase-I pilot study published in 1996 in three healthy men. Its safety record consists of roughly twenty published case reports.
That imbalance — three people studied for effect, twenty written up for harm — is the whole story, and it is the reason this page exists. If you are researching Melanotan II, what you most need is not a protocol. It is an accurate account of what is known, what is assumed, and what is being sold to you under a name that borrows credibility from a different, approved drug.
Melanotan II is not the drug the FDA approved
This is the most consequential confusion in the category, and it is exploited constantly in marketing.
| Melanotan II | Afamelanotide (SCENESSE) | |
|---|---|---|
| Also called | MT-II, MT-2, “tan jab” | Historically “melanotan I” — a legacy name best avoided |
| Receptor activity | Non-selective across MC1, MC3, MC4 and MC5 | Predominantly MC1 |
| Approval | None, in any country | FDA-approved 8 October 2019; EU 2014 |
| Approved for | — | Increasing pain-free light exposure in adults with erythropoietic protoporphyria, a rare genetic photosensitivity disorder |
| How it is given | Self-injected vial or nasal spray from unregulated suppliers | Subcutaneous implant placed by a clinician |
| Is it a cosmetic tanning product? | Marketed as one, never approved as one | No |
The shared “melanotan” naming is an accident of 1980s University of Arizona laboratory nomenclature. Afamelanotide’s approval for a rare porphyria says nothing whatsoever about the safety of Melanotan II for cosmetic use, and any page that implies otherwise is misleading you.
How Melanotan II works, and why that explains the side effects
Melanin production in the skin is switched on by α-MSH acting at the melanocortin-1 receptor (MC1R) on melanocytes. Melanotan II mimics that signal, but it is not selective: it also activates MC3, MC4 and MC5 receptors, which sit in the brain, the gut and elsewhere.
In plain terms, this is a compound that was designed to hit one switch and ended up hitting four. The MC4 activity is why nausea, appetite suppression, yawning and spontaneous erections appear so consistently in reports — those are not idiosyncratic reactions, they are the predictable consequence of the molecule’s lack of selectivity. Langan and colleagues reviewed this pharmacology in the British Journal of Dermatology in 2010.
What the evidence actually consists of
For cosmetic tanning in humans, the published efficacy evidence is one study: Dorr and colleagues, Life Sciences, 1996 — a phase-I pilot in three healthy men. There has never been a controlled trial of Melanotan II for cosmetic tanning. Development was discontinued by its commercial sponsor in 2000.
Be alert to a specific sleight of hand here. The larger and better-known tanning studies published around 2000 used melanotan-I, which became afamelanotide — a different molecule. Those results are routinely relabelled as Melanotan II evidence in product marketing. They are not.
On the other side of the ledger sits a body of case reports, which we cover below. A 2021 review by Wensink and colleagues in Expert Review of Clinical Pharmacology, and a 2017 review by Habbema and colleagues in the International Journal of Dermatology, both describe a literature made up of individual reports rather than controlled data.
What is documented on the harm side
Changes to moles are the most consistently reported effect. There are published reports of new moles appearing and existing ones darkening, sometimes very quickly. Schulze and colleagues, in the European Journal of Dermatology in 2014, described eruptive naevi and darkening of pre-existing naevi within twenty-four hours of a single injection. Cousen and colleagues reported eruptive melanocytic naevi in the British Journal of Dermatology in 2009; Reid and colleagues described multiple new atypical naevi within a week of two injections in the Irish Medical Journal in 2013. Mang and colleagues documented the changes with sequential dermoscopy in Der Hautarzt in 2012.
Melanoma has been reported in association with use — and the wording there is deliberate. Case reports include Hjuler and Lorentzen in Dermatology (2014), Paurobally and colleagues in the British Journal of Dermatology (2011), Ong and Bowling in the Australasian Journal of Dermatology (2012), and more recently a report of oral mucosal melanoma in the International Journal of Oral and Maxillofacial Surgery (2025).
Here is the honest reading of those reports, which most pages get wrong in one direction or the other. No published author claims Melanotan II causes melanoma. A systematic review by Javed and colleagues in the International Journal of Surgery (2013) found no conclusive evidence of causation, and the 2021 Wensink review suggested the excess risk in users “can probably be explained by more UV exposure,” since people using a tanning compound tend to also seek sun. Almost every melanoma case in the literature involved concurrent sunbed or sun exposure, and several involved other risk factors.
But that does not make the signal unimportant — it relocates it. The defensible concern is surveillance: a compound that rapidly changes the number and appearance of your moles makes it harder for you, and for a clinician, to spot the one lesion that matters. Combine that with a population that is deliberately increasing its UV exposure, and the risk is real even if the molecule itself is never shown to be carcinogenic.
Serious systemic events have been reported, though rarely. The published record includes rhabdomyolysis with sympathomimetic toxicity following a six-milligram subcutaneous injection (Nelson and colleagues, Clinical Toxicology, 2012), renal infarction (Peters and colleagues, CEN Case Reports, 2020), posterior reversible encephalopathy syndrome (Kaski and colleagues, Annals of Internal Medicine, 2013), and priapism (Dreyer and colleagues, BMJ Case Reports, 2019). More common and less dramatic: nausea, vomiting, facial flushing, appetite loss, yawning and spontaneous erections.
And then there is what is actually in the vial. In August 2026 Australia’s Therapeutic Goods Administration published laboratory testing of five bottles of one product labelled as containing 30 mg; the measured content ranged from 22 mg to 54 mg. For a compound bought online and injected at home, the identity, concentration, purity and sterility of the contents are unverified by anyone.
Melanotan II is not sun protection
This needs stating directly, because it is the claim most often made for the compound and it is the one with the most potential to cause harm.
A tan is not meaningfully protective. The photoprotection offered by even a deep natural tan is small — the figure usually cited in dermatology literature is equivalent to a sun protection factor of around 3 or 4, against the SPF 30 or higher that is actually recommended. More importantly, no study has demonstrated that pigmentation induced by Melanotan II reduces skin cancer risk, DNA damage or photoageing. There is no evidence base for that claim at all.
So the practical implication is the opposite of what people assume. A compound that makes you look tanned, while encouraging more time in the sun and simultaneously changing your moles, should increase your sun-protection vigilance rather than relax it. Sunscreen, protective clothing, shade and avoiding peak hours remain the only measures with evidence behind them. If your goal is an even skin tone or improved skin quality, that is a conversation about aesthetic treatments such as microneedling with PRP — approaches with far better-characterised risk profiles.
Why this page does not give you a dosing protocol
You will find milligram-per-day schedules, loading phases and maintenance protocols on vendor sites and forums. We are not reproducing them, and the reason is not squeamishness.
There is no established dose, because there is no approved use and no dose-ranging trial in humans beyond the 1996 pilot in three people. Every protocol circulating online is derived from user reports rather than from evidence. Publishing one would mean presenting a number as clinical guidance when no clinical guidance exists — and for a compound that is self-injected from unregulated supply at unverified concentration, that is the point at which an educational page becomes a hazard.
If you are considering this compound, the conversation to have is with a clinician who can see your skin, not with a dosing chart.
Where Melanotan II stands with regulators
- The FDA has never approved it for any indication or route.
- It is not on the FDA’s 503A list of bulk drug substances permitted for compounding. It was added to Category 2 — substances raising significant safety risks — in September 2023, and later removed because the nominations were withdrawn, not because of any safety clearance. It currently sits in no category at all, which means a 503A compounding pharmacy has no lawful basis to use it. This is a different position from a peptide such as GHK-Cu, and the distinction between the categories is worth understanding before assuming any compounded peptide is equivalent to any other.
- The FDA’s own published risk language is explicit. On its page covering bulk drug substances that may present significant safety risks, the agency states that compounded drugs containing Melanotan II may pose a risk of immunogenicity due to the potential for aggregation or peptide-related impurities, and that published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.
- Regulators internationally have issued consumer warnings since 2007: Norway and Denmark from 2007 to 2008, the UK Medicines and Healthcare products Regulatory Agency in 2008 and again in 2013, Ireland’s Health Products Regulatory Authority most recently in August 2023, and Australia’s TGA, which classifies it as prescription-only, has no approved product on its register, and issued a safety alert in August 2026.
Who should not consider Melanotan II
- Anyone with a personal or family history of melanoma or other skin cancer.
- Anyone with atypical, dysplastic or numerous moles, or a familial atypical multiple mole syndrome. A published case describes a teenager with FAMMM syndrome whose lesions changed after use.
- Anyone who is not willing to have regular skin checks. If moles are going to change, someone qualified needs to be watching them.
- Anyone with significant cardiovascular disease, given the reported sympathomimetic effects.
- Pregnancy and breastfeeding.
- Anyone under 18.
- Anyone intending to use it to spend more time in the sun or on a sunbed — that combination is precisely the pattern that appears in the published melanoma reports.
If you have moles you are unsure about, the right next step is a dermatologist, not a peptide. We will say that to your face in a consultation, and we would rather say it here too.
Frequently asked questions
How long does Melanotan II take to tan?
There is no reliable answer, because there is no controlled trial measuring it. Reports describe pigmentation developing over days to weeks, varying considerably with baseline skin type and with how much UV exposure the person is also getting — which is the part that carries the risk. We would rather tell you the timeline is unstudied than quote a number from a forum.
Does Melanotan II burn fat?
No. It frequently suppresses appetite, which is an expected effect of activating MC4 receptors in the brain, and some people lose weight as a result of eating less. That is not fat-burning in any pharmacological sense, it is not an approved or studied use, and appetite suppression from an unregulated injectable is not a weight-management strategy. If weight is the goal, our medically supervised weight management programme is the appropriate route.
Does Melanotan II affect eye colour?
There is no good evidence that it does. Claims about iris darkening circulate online but are not supported by published human data. What is documented is pigmentation change in skin, moles, freckles and — in at least one report — oral mucosa and nails.
Does Melanotan II affect the heart?
It can. The compound is non-selective across melanocortin receptors and has reported sympathomimetic effects — the published rhabdomyolysis case involved a sympathomimetic toxidrome, and the FDA names that among the serious adverse events in the case-report literature. Anyone with cardiovascular disease, arrhythmia or uncontrolled hypertension should not be considering this compound.
Is Melanotan II legal in the United States?
It is not an approved drug, and it is not on the FDA’s list of substances permitted for pharmacy compounding under section 503A. Products sold online as “research chemicals” are not approved medicines and are not manufactured to pharmaceutical standards. It is also almost certainly prohibited in sport: it is not named individually on the World Anti-Doping Agency list, but the S0 category captures substances with no approval from any health regulator, which describes Melanotan II exactly. A drug-tested athlete should assume it is prohibited and check with their anti-doping organisation.
Is Melanotan II the same as the tanning injection my dermatologist mentioned?
Almost certainly not. The only melanocortin product approved in the United States is afamelanotide (SCENESSE), an implant placed by a clinician for people with erythropoietic protoporphyria, a rare genetic photosensitivity disorder. It is not prescribed for cosmetic tanning. If a product is being sold to you for a tan, it is not the approved one.
Important medical disclaimer
These statements have not been evaluated by the Food and Drug Administration. Melanotan II is not an FDA-approved drug and is not approved in the United States or any other country for any indication; it is not on the FDA’s 503A list of bulk drug substances permitted for compounding, and the FDA has stated that compounded preparations containing it may pose a risk of immunogenicity and that published case reports describe serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. This article is educational. It is not medical advice, not a substitute for evaluation by a qualified clinician, not a recommendation to use Melanotan II, and not a claim that it diagnoses, treats, prevents or cures any condition. Melanotan II is not a sunscreen and is not a substitute for sun protection. It is not appropriate for people with a personal or family history of melanoma or skin cancer, atypical or numerous moles, significant cardiovascular disease, during pregnancy or breastfeeding, or under 18. Any new, changing, asymmetric, irregularly bordered, multi-coloured or enlarging mole should be assessed by a dermatologist promptly. Do not obtain or self-administer research-grade peptides purchased online.
Sources referenced
Dorr RT, Lines R, Levine N, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sciences, 1996;58(20):1777–1784. · Langan EA, Nie Z, Rhodes LE. “Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’?” British Journal of Dermatology, 2010;163(3):451–455. · Hjuler KF, Lorentzen HF. “Melanoma associated with the use of melanotan-II.” Dermatology, 2014;228(1):34–36. · Paurobally D, Jason F, Dezfoulian B, Nikkels AF. “Melanotan-associated melanoma.” British Journal of Dermatology, 2011;164(6):1403–1405. · Ong S, Bowling J. “Melanotan-associated melanoma in situ.” Australasian Journal of Dermatology, 2012;53(4):301–302. · Yassin Alsabbagh A, Bhujel N, Singh RP. “Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?” International Journal of Oral and Maxillofacial Surgery, 2025;54(9):806–808. · Cousen P, Colver G, Helbling I. “Eruptive melanocytic naevi following melanotan injection.” British Journal of Dermatology, 2009;161(3):707–708. · Schulze F, Erdmann H, et al. “Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II.” European Journal of Dermatology, 2014;24(1):107–109. · Mang R, Krahl D, Assmann T. “Dermoscopic changes in melanocytic nevi during use of melanotan II.” Der Hautarzt, 2012;63(11):880–884. · Reid C, Fitzgerald T, Fabre A, Kirby B. “Atypical melanocytic naevi following melanotan injection.” Irish Medical Journal, 2013;106(5):148–149. · Nelson ME, Bryant SM, Aks SE. “Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.” Clinical Toxicology, 2012;50(10):1169–1173. · Peters B, Hadimeri H, Wahlberg R, Afghahi H. “Melanotan II: a possible cause of renal infarction.” CEN Case Reports, 2020;9(2):159–161. · Dreyer BA, et al. “Melanotan-induced priapism: a hard-earned tan.” BMJ Case Reports, 2019. · Javed M, Yarrow J, Hemingtongorse S. International Journal of Surgery, 2013;11(8):677. · Wensink D, Wagenmakers MAEM, Langendonk JG. Expert Review of Clinical Pharmacology, 2021;14(2):151–160. · Habbema L, Halk AB, Neumann M, Bergman W. “Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.” International Journal of Dermatology, 2017;56(10):975–980. · US Food and Drug Administration, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” and the 503A bulk drug substances category lists. · Australian Therapeutic Goods Administration, safety alert on melanotan II products, August 2026. · UK Medicines and Healthcare products Regulatory Agency, melanotan warnings, 2008 and 2013. · Irish Health Products Regulatory Authority, safety notice on Melanotan 2 self-tan products, August 2023.
Medically reviewed by Biana Borchenko, FNP-BC (A4M) — Robertson Wellness & Aesthetics, Beverly Hills.
